Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Author:

Bona Kira1ORCID,Brazauskas Ruta23,He Naya2,Lehmann Leslie4,Abdel-Azim Hisham5,Ahmed Ibrahim A6,Al-Homsi A Samer7,Aljurf Mahmoud8,Arnold Staci D.9ORCID,Badawy Sherif M1011,Battiwalla Minoo12,Beattie Sara1314,Bhatt Neel S.15,Dalal Jignesh16,Dandoy Christopher E.17ORCID,Diaz Miguel Angel18ORCID,Frangoul Haydar A.19,Freytes César O.20ORCID,Ganguly Siddhartha21,George Biju22ORCID,Gomez-Almaguer David23ORCID,Hahn Theresa24,Kamble Rammurti T.25,Knight Jennifer M.26,LeMaistre C. Fred12ORCID,Law Jason27,Lazarus Hillard M.28,Majhail Navneet S.29ORCID,Olsson Richard F.3031ORCID,Preussler Jaime32,Savani Bipin N.33ORCID,Schears Raquel34,Seo Sachiko35ORCID,Sharma Akshay36ORCID,Srivastava Alok37ORCID,Steinberg Amir38,Szwajcer David39ORCID,Wirk Baldeep40,Yoshimi Ayami41,Khera Nandita42,Wood William A.43,Hashmi Shahrukh4445ORCID,Duncan Christine N.4,Saber Wael2

Affiliation:

1. Division of Population Sciences, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

2. Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, and

3. Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Milwaukee, WI;

4. Department of Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Harvard Medical School, Boston, MA;

5. Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA;

6. Department of Hematology Oncology and Bone Marrow Transplantation, Children’s Mercy Hospitals and Clinics, Kansas City, MO;

7. New York University Langone Health, New York, NY;

8. Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia;

9. Aflac Cancer and Blood Disorder Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA;

10. Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL;

11. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL;

12. Sarah Cannon Blood Cancer Network, Nashville, TN;

13. Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, AB, Canada;

14. Department of Oncology, University of Calgary, Calgary, AB, Canada;

15. Fred Hutchinson Cancer Research Center, Seattle, WA;

16. Rainbow Babies and Children’s Hospital, Cleveland Case Western Reserve School of Medicine, Cleveland, OH;

17. Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH;

18. Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain;

19. Children’s Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN;

20. Texas Transplant Institute, San Antonio, TX;

21. Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS;

22. Department of Haematology, Christian Medical College, Vellore, India;

23. Hospital Universitario Dr. José E. González, Universidad Autónoma de Nuevo León, Monterrey, Mexico;

24. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY;

25. Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX;

26. Department of Psychiatry, Medical College of Wisconsin, Milwaukee, WI;

27. Division of Pediatric Hematology/Oncology, Floating Hospital for Children at Tufts Medical Center, Boston, MA;

28. University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;

29. Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

30. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;

31. Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;

32. CIBMTR, National Marrow Donor Program/Be The Match, Minneapolis, MN;

33. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

34. Department of Emergency Medicine, University of Central Florida, Orlando, FL;

35. Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan;

36. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN;

37. Centre for Stem Cell Research, Christian Medical College, Vellore, India;

38. Division of Hematology and Oncology, Mount Sinai Hospital, New York, NY;

39. CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada;

40. Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA;

41. Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg Medical Center, Freiburg, Germany;

42. Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ;

43. Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC;

44. Department of Internal Medicine, Mayo Clinic, MN; and

45. Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

Abstract Social determinants of health, including poverty, contribute significantly to health outcomes in the United States; however, their impact on pediatric hematopoietic cell transplantation (HCT) outcomes is poorly understood. We aimed to identify the association between neighborhood poverty and HCT outcomes for pediatric allogeneic HCT recipients in the Center for International Blood and Marrow Transplant Research database. We assembled 2 pediatric cohorts undergoing first allogeneic HCT from 2006 to 2015 at age ≤18 years, including 2053 children with malignant disease and 1696 children with nonmalignant disease. Neighborhood poverty exposure was defined a priori per the US Census definition as living in a high-poverty ZIP code (≥20% of persons below 100% federal poverty level) and used as the primary predictor in all analyses. Our primary outcome was overall survival (OS), defined as the time from HCT until death resulting from any cause. Secondary outcomes included relapse and transplantation-related mortality (TRM) in malignant disease, acute and chronic graft-versus-host disease, and infection in the first 100 days post-HCT. Among children undergoing transplantation for nonmalignant disease, neighborhood poverty was not associated with any HCT outcome. Among children undergoing transplantation for malignant disease, neighborhood poverty conferred an increased risk of TRM but was not associated with inferior OS or any other transplantation outcome. Among children with malignant disease, a key secondary finding was that children with Medicaid insurance experienced inferior OS and increased TRM compared with those with private insurance. These data suggest opportunities for future investigation of the effects of household-level poverty exposure on HCT outcomes in pediatric malignant disease to inform care delivery interventions.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3